Madrigal Gets Conditional Nod for MASH Drug Rezdiffra in EU

Madrigal Pharmaceuticals secured conditional EU approval for Rezdiffra, its noncirrhotic MASH treatment, making it the first and only therapy approved for the condition in the European Union, with a Q4 2025 launch anticipated. Despite this significant regulatory milestone, MDGL shares declined 3% on investor concerns regarding direct competition from Novo Nordisk's Wegovy, which recently gained accelerated FDA approval for MASH. This highlights the market's focus on the evolving competitive landscape within the MASH therapeutic space, even as Rezdiffra's U.S. commercial launch has shown strong initial traction with $212.8 million in Q2 2025 sales.

Analysis

Madrigal Pharmaceuticals (MDGL) has achieved a significant regulatory milestone with the European Commission's conditional marketing authorization for Rezdiffra, establishing it as the first approved therapy for noncirrhotic MASH in the EU. This approval was widely anticipated, following a positive CHMP opinion, and is supported by positive phase III MAESTRO-NASH data. However, the market's reaction was negative, with MDGL shares declining 3%, as investor focus immediately shifted to the formidable competitive threat posed by Novo Nordisk’s Wegovy. Wegovy recently received an accelerated FDA approval for MASH, and analysts suggest its established safety profile and broad metabolic benefits could position it as a primary treatment option. This competitive overhang is overshadowing Rezdiffra's own impressive commercial execution in the United States, where its launch is demonstrating strong momentum with Q2 2025 sales reaching $212.8 million—a 55% sequential increase—and a patient base exceeding 23,000. The situation illustrates that while Rezdiffra has a first-mover advantage in the EU, its long-term market share will be heavily contested, particularly by established GLP-1 therapies entering the indication.

Key Decisions for Investors

• Investors should closely monitor the prescription and sales data for both Rezdiffra and Wegovy in the MASH indication to assess the real-world competitive dynamics and market share capture.
• Given the strong US launch performance, tracking Rezdiffra's sequential sales growth and patient uptake in the coming quarters is critical to evaluating its standalone commercial viability against the competitive narrative.
• Consider the current stock weakness as a potential entry point for long-term positions, but weigh this against the significant risk that GLP-1 drugs like Wegovy may become the preferred treatment for MASH, potentially limiting Rezdiffra's peak sales potential.
• Note that the EU launch is not scheduled until Q4 2025, making near-term catalysts dependent on US commercial results and any updates on Rezdiffra's long-term safety and efficacy data required for full regulatory approval.